Placental Insufficiency and Neonatal Vulnerability: Organ‐Specific Mechanisms Shaping Early‐Life Health

ABSTRACT

Placental insufficiency is a central pathological condition underlying fetal growth restriction and is strongly associated with adverse outcomes during the neonatal period. Although epidemiological and clinical studies have consistently linked compromised placental function to neonatal respiratory, neurological, gastrointestinal, and infectious morbidity, the mechanisms through which placental insufficiency translates into organ‐specific neonatal vulnerability remain unclear. Increasing evidence from human observations and experimental animal models indicates that placental insufficiency disrupts coordinated fetal development through alterations in perfusion, vascular patterning, cellular differentiation, barrier maturation, and immune responsiveness, rather than through uniform growth failure. This review summarizes current progress in the understanding of organ‐specific mechanisms by which placental insufficiency shapes neonatal vulnerability, with a focus on the lung, brain, intestine, and immune system. We further discuss how these developmental perturbations interact with postnatal environmental exposures and highlight future perspectives for identifying at‐risk infants and developing targeted strategies to mitigate adverse neonatal outcomes.

1. Introduction

Pre‐eclampsia (PE) and fetal growth restriction (FGR) are associated conditions that share a common underlying pathology, which is placental dysfunction. Placental dysfunction is a leading medical cause of preterm birth [1], and despite advancements in neonatal intensive care, the long‐term health of an affected offspring remains a growing concern [2]. Given the global trend of delayed childbearing, the incidence of PE is increasing [3], and appropriate medical interventions for offspring exposed to this intrauterine environment are expected to contribute to improved long‐term health outcomes.

Extensive pathological studies have characterized placental dysfunction by reduced uteroplacental perfusion, chronic inflammation, and abnormal trophoblast differentiation and invasion [4]. Intrauterine inflammation and ischemia are considered principal factors affecting fetuses, and such placental pathology is presumed to exert molecular‐level effects on fetal development. Placental pathology is associated with neonatal adverse outcomes [5, 6]. Accumulating evidence suggests that placental insufficiency compromises fetal growth and short‐term survival, with lasting effects on organ development, immune system programming, and metabolic regulation. Later in life, these intrauterine injuries may predispose individuals to numerous health disorders, although the precise molecular mechanisms remain unclear.

FGR diagnosed near or at term typically requires less intensive neonatal support than those diagnosed at early‐onset. Multiple cohort studies have shown that FGR carries increased risks of neurocognitive and cardiometabolic sequelae later in life [7], which is consistent with the developmental origins of health and disease (DOHaD) paradigm [8]. In contrast, FGR, identified during the preterm period, is more frequently accompanied by abnormal umbilical artery Doppler velocimetry and oligohydramnios [9]. These fetuses face a double burden: prematurity due to preterm birth and in utero stress due to chronic hypoxia and malnutrition. Increasing evidence supports the clinical burden encountered by these infants in multiple organs during the neonatal period, thereby affecting their general development.

In this review, we focused on FGR due to placental dysfunction, excluding cases associated with chromosomal abnormalities, structural malformations, or maternal–fetal infections. FGR due to twin pregnancies is beyond the scope of this review. We summarized clinical and mechanistic insights into how placental dysfunction affects offspring health, encompassing neonatal, childhood, and adult outcomes associated with PE and FGR. Additionally, we examined maternal and placental pathways, including angiogenic imbalance, hypoxia signaling, immune dysregulation, and endocrine and metabolic perturbations, which connect this maternal syndrome with fetal exposure. Next, organ‐specific responses that plausibly mediate long‐term disease risk were outlined. Finally, we discussed translational opportunities for biomarker‐guided stratification and preventive interventions aimed at altering life‐course risk (Figure 1).

FIGURE 1.

Placental insufficiency‐driven developmental perturbations underlying neonatal vulnerability. Placental insufficiency disrupts coordinated fetal development through impaired perfusion, hypoxia, and altered stress responses, leading to organ‐specific structural and functional immaturity. These alterations differentially affect the lung, brain, intestine, and immune system and manifest as increased vulnerability to adverse outcomes during the neonatal period, which may be further modified by postnatal environmental factors.

2. Health Risks in Offspring Exposed to Placental Dysfunction

Epidemiological studies have demonstrated that offspring exposed to maternal PE or born as FGR are at increased risk of various morbidities (Table 1). We reviewed these morbidities from the neonatal period through childhood, highlighting how placental dysfunction shapes postnatal health trajectories.

TABLE 1.

Organ‐specific neonatal outcomes and structural–cellular alterations in placental insufficiency.

Organ	Adverse outcomes during the neonatal period	Structural/cellular alterations
Lung	Bronchopulmonary dysplasia	Type II alveolar epithelial cells: preserved surfactant production with delayed structural maturation
	Pulmonary hemorrhage
		Alveolar epithelial and mesenchymal cells: reduced secondary septation and simplified distal airspaces
	Ventilator support
	Primary surfactant deficiencynot consistently observed	Pulmonary endothelial cells: reduced capillary density and decreased capillary–alveolar apposition
Brain	Increased risk of later neurodevelopmental impairment	Endothelial cells and pericytes: altered microvascular organization within the neurovascular unit
		Microglia: altered activation states and inflammatory priming
		Oligodendrocyte lineage cells: delayed maturation and reduced myelin formation
	Major brain injuries (IVH, PVL)not consistently observed
		Neurons: increased vulnerability to cell loss and impaired circuit development
Intestine	Feeding intolerance	Goblet cells: reduced mucus production
		Paneth cells: decreased antimicrobial peptide expression
		Tight junction–forming epithelial cells: increased epithelial permeability
	Necrotizing enterocolitis
	Meconium related ileus
	Spontaneous intestinal perforationnot consistently observed
Immune system	Sepsis	Innate immune cells (monocytes, neutrophils): altered activation thresholds and cytokine responsiveness
	Increased susceptibility to infection
		T lymphocytes: biased inflammatory and regulatory responses
	Consistent immune cell depletionnot observed

Note: This table summarizes adverse outcomes during the neonatal period and corresponding structural, cellular, and mechanistic features observed in major organs affected by placental insufficiency. Rather than uniform growth failure, placental insufficiency induces organ‐specific patterns of developmental immaturity that predispose growth‐restricted infants to neonatal morbidity.

2.1. Neonatal Outcomes

In the neonatal period, outcomes include higher incidences of complications such as respiratory distress, gastrointestinal dysfunction, feeding intolerance, and neurological complications. Part of this burden is attributable to prematurity because maternal disease or fetal compromise often necessitates early delivery. However, growth‐restricted infants exhibit distinct vulnerability profiles that reflect the biology of placental insufficiency, even after matching for gestational age.

2.2. Respiratory System

According to a review on the association between FGR and respiratory disorders, there was a similar number of data stratifications supporting either decreased or increased risk of respiratory distress syndrome morbidity, indicating no consistent trend [10]. Preterm infants, particularly those with small for gestational age (SGA), are reported to have a high risk of pulmonary hemorrhage, a severe condition associated with early postnatal death, although hypocoagulability is also thought to play a contributory role [11]. Additionally, there is a greater propensity for bronchopulmonary dysplasia among extremely preterm infants [1, 12, 13]. Therefore, respiratory morbidity is strongly affected by gestational age at birth, and FGR serves as an additional stressor. Reduced lung volume and aberrant main pulmonary artery Doppler profiles identify growth‐restricted fetuses at increased risk of early neonatal respiratory morbidity [14].

2.3. Neurological System

The association between FGR and intraventricular hemorrhage (IVH) or periventricular leukomalacia (PVL) remains inconsistent across studies. In the ACTION cohort study focusing on neonatal outcomes after preterm birth [1], placentation‐related disorders (hypertensive disorders of pregnancy and FGR) were associated with lower incidences of IVH and PVL than cases with presumed infection/inflammation (spontaneous preterm labor and premature rupture of membranes), after adjustment for gestational age. In contrast, another retrospective study reported that FGR infants with abnormal umbilical artery Doppler findings had a significantly higher incidence of severe IVH or PVL compared with non‐FGR infants, whereas FGR infants with normal Doppler waveforms showed a non‐significant or lower risk [15]. Therefore, it is impractical to assume that FGR uniformly increases the risk of IVH or PVL, and clinical interpretation should consider the composite effect of placental dysfunction, inflammation, and hemodynamic instability in each case. Term neonates with FGR do not carry increased risk of hypoxic ischemic encephalopathy [16]. Importantly, neuroimaging studies demonstrate that adverse effects extend beyond overt lesions: fetuses with late‐onset FGR at 37 weeks of gestation had a different pattern of cortical development assessed on magnetic resonance imaging [17], supporting the existence of in utero brain reorganization, even in clinically stable infants, foreshadowing later cognitive and motor difficulties.

2.4. Gastrointestinal System

Gastrointestinal morbidity is another hallmark of the growth‐restricted phenotype. Preterm infants with FGR encounter feeding intolerance and a higher risk of necrotizing enterocolitis (NEC) [18] and meconium related ileus (MRI) [19]. Although a clear association between spontaneous intestinal perforation (SIP) and FGR has not been established, preterm infants born to mothers with PE exhibit a significantly higher incidence of SIP compared with those born to normotensive mothers [20]. These features explain the frequent need for prolonged parenteral nutrition, which in turn increases infectious and metabolic complications. It delays the establishment of enteral nutrition. Among preterm infants diagnosed with FGR, absent or reversed end‐diastolic flow in the umbilical artery and in the ductus venosus had significantly higher feeding intolerance, NEC, and SIP rates and achieved full enteral feeds later compared to normal Doppler controls [21]. Additionally, median time from the onset of Doppler abnormalities in the umbilical artery, middle cerebral artery, or ductus venosus to delivery was significantly longer in patients with intestinal disorders than in those without [22]. Collectively, these findings suggest that fetal Doppler abnormalities among preterm infants with FGR serve as a clinical parameter reflecting the effect of placental insufficiency on intestinal vulnerability.

2.5. Immune System

Although the risk of sepsis in infants with FGR decreases with advancing gestational age, it remains higher compared with normally grown infants. However, this increased risk may in part reflect the need for intensive medical interventions, such as prolonged use of central venous catheters, after birth. Additionally, infants with FGR tend to have smaller thymic size, and reduced thymic size has been associated with a higher incidence of postnatal sepsis [23, 24]. Infants with FGR are more likely to exhibit a low‐grade fetal inflammatory response (based on elevated umbilical cord CRP), and are at increased risk of early‐onset sepsis within 72 h after birth [25]. In fetuses with FGR, several studies have shown alterations in leukocyte count and composition, reflecting impaired immune development [26, 27].

Together, the respiratory, neurologic, gastrointestinal, and immunologic vulnerabilities create a complex postnatal course that requires multidisciplinary neonatal care and tailored follow‐up.

2.6. Childhood Outcomes

Neurodevelopmental diagnoses reflect central nervous system vulnerability. Evidence linking SGA with cerebral palsy (CP) is more consistent at term than that among preterm populations. Large registry studies show that term SGA, particularly severe SGA, is robustly associated with higher risk of CP [28, 29]. In contrast, association varies and appears strongly dependent on gestational age in preterm cohorts; some studies show little or no excess risk at very low gestational ages [1, 29], whereas others have reported an increased risk of CP among preterm infants with SGA [30]. These findings may in part reflect the effect of associated neonatal morbidities and mortality among the most immature infants, as well as other etiologies for preterm birth, such as chorioamnionitis or inflammation‐related causes in the control groups. Nevertheless, in moderate‐to‐late preterm (32–36 weeks) infants, a meta‐analysis of seven studies demonstrated that SGA confers an approximately two‐fold higher risk of CP (pooled odds ratio [OR], 2.34; 95% confidence interval [CI]: 1.43–3.82) [31]. Beyond motor disability, there was an increased likelihood of learning disorders, language delay, and social communication difficulties. In very preterm infants born with gestational age ≤ 32 weeks, FGR was associated with a significantly increased risk of poor neurodevelopmental outcome at 24 months of corrected age compared with age‐matched appropriate for gestational age (AGA) infants [32]. Follow‐up studies later in childhood also reported psychomotor developmental delay and impairment of language abilities [33, 34]. School‐age assessments consistently demonstrate cognitive and behavioral difficulties, including lower full‐scale IQ and deficits in executive functions (e.g., working memory, cognitive flexibility), particularly among preterm FGR children [35, 36, 37]. However, increased rates of attention problems and autism spectrum conditions are observed in term and preterm FGR groups [38].

Large population‐based studies have examined the relationship between FGR and later respiratory or allergic morbidity while stratifying according to gestational age. Preterm and term FGR children show increased risks of asthma, wheezing, and lower lung function; however, the association tends to be more pronounced among term‐born FGR children, whereas in preterm infants, the contribution of FGR is often masked by the dominant effects of prematurity and bronchopulmonary dysplasia [39, 40]. Additionally, term‐born FGR has been linked with a higher incidence of allergic diseases such as atopic dermatitis [41]. These findings suggest that prenatal growth impairment alters airway and immune development, with gestational age modifying the magnitude of postnatal respiratory and allergic vulnerability.

Cardiometabolic health trajectories begin to diverge in middle childhood. Children with a history of SGA show higher systolic blood pressure percentiles and blunted nocturnal dipping on ambulatory monitoring, consistent with early vascular programming, with particularly elevated systolic pressures after very preterm birth due to early‐onset FGR [42, 43].

Although children born with SGA often show elevated insulin resistance indices and an adverse lipid profile (higher triglycerides and lower high density lipoprotein cholesterol), even among those with normal body mass index, implying prenatal programming beyond postnatal lifestyle [44]. Studies stratified by gestational age (term vs. preterm) remain limited. Therefore, further studies are needed to clarify how this programming differs between term and preterm SGA groups.

Although gastrointestinal morbidities are more common in the neonatal period among infants with FGR, no clear or consistent association has been reported between FGR and gastrointestinal diseases, such as inflammatory bowel disease or chronic constipation during school age.

These early‐life alterations are thought to persist into adulthood, contributing to increased risks of cardiovascular, metabolic, and neuropsychiatric disorders, as postulated by the DOHaD hypothesis [45, 46].

3. Molecular Mechanisms Linking Placental Dysfunction to Developmental Programming

The placenta plays a central role in shaping the fetal environment through oxygen and nutrient supply regulation, endocrine signaling, and immunological tolerance. When placental function is impaired, fetuses are exposed to a constellation of stressors, including chronic hypoxia, oxidative stress, systemic inflammation, nutrient restriction, and altered endocrine and growth factor signaling, often during critical periods of rapid growth and functional maturation.

The placental pathology of maternal phenotype of PE has been extensively studied and should be referred to in other review articles. Briefly, the mechanism of angiogenic imbalance includes: elevated circulating soluble fms‐like tyrosine kinase‐1 antagonizes vascular endothelial and placental growth factors, neutralizing their pro‐angiogenic and cytoprotective actions, and resulting in the systemic endothelial injury. Hypoxic conditions and inflammatory cytokines within placental tissues can serve as factors shaping the intrauterine environment [47, 48, 49, 50]. Additionally, immune maladaptation bridges maternal and placental pathology. Normal pregnancy requires finely tuned tolerance toward a semi‐allogeneic fetus, mediated by regulatory T cells, specialized uterine natural killer cells, and tolerogenic dendritic cells at the maternal‐fetal interface. In PE, this equilibrium is perturbed: T‐helper 1 and T‐helper 17 responses expand, decidual regulatory T cells decline, and innate immune cells adopt pro‐inflammatory programs [51]. Cytokines, such as tumor necrosis factor family members and interferons, impair trophoblast invasion and spiral artery remodeling, while circulating autoantibodies, including those targeting the angiotensin II type‐1 receptor, further potentiate vasoconstrictive and anti‐angiogenic signaling [48].

These stressors exert systemic effects that indirectly shape fetal development through the placenta, while the fetoplacental barrier limits direct exposure to maternal immune or anti‐angiogenic factors. Epigenetic reprogramming, including altered DNA methylation and histone modification, creates long‐lasting transcriptional memory [52, 53]. In parallel, disruption of developmental signaling pathways, such as the wingless‐related integration site (Wnt), bone morphogenetic protein, insulin‐like growth factor, and mechanistic target of rapamycin, within organ‐specific microenvironments mediates tissue‐level maladaptation, can link systemic stress to localized growth, and cause differentiation defects [54, 55, 56].

4. Organ‐Specific Responses

To date, direct cellular or molecular analyses of fetal organs in growth‐restricted pregnancies using human tissue remain extremely limited, owing to substantial technical and ethical constraints on sampling. Therefore, experimental animal studies have provided important clues to the molecular and cellular processes by which placental insufficiency perturbs coordinated fetal organ development. In the following sections, we focused on organs most consistently implicated in adverse outcomes during the neonatal period (the lung, brain, intestine, and immune system) and summarized organ‐specific molecular and cellular pathways through which placental insufficiency disrupts coordinated fetal development and programs postnatal disease vulnerability (Table 1).

4.1. Lung

Morphometric and experimental studies indicate that FGR does not uniformly reduce total lung volume or lung weight relative to body weight, suggesting that global lung hypoplasia is not the dominant phenotype. Similarly, surfactant protein expression and biochemical maturation of type II alveolar epithelial cells are often preserved at birth in FGR models, indicating that primary surfactant deficiency is not a consistent feature. Instead, the dominant abnormalities are histological and architectural: the lungs in FGR exhibit simplified distal airspaces, increased alveolar wall thickness, reduced radial alveolar counts, and impaired secondary septation, reflecting disrupted alveolarization rather than delayed canalicular–saccular maturation [57].

At the tissue level, these structural abnormalities are accompanied by impaired pulmonary microvascular development, characterized by reduced capillary density and decreased expression of angiogenic markers such as vascular endothelial growth factor and the von Willebrand factor. Experimental inhibition of angiogenesis during critical windows of lung development is sufficient to reproduce defective alveolarization [58], thereby underscoring the tight coupling between vascular growth and alveolar formation. Additionally, alterations in alveolar wall composition, including reduced cartilage and epithelial components in proximal airways and persistent abnormalities in mucus‐producing elements, have been described, suggesting long‐lasting effects on airway structure and defense mechanisms, even when gross airway dimensions normalize postnatally.

Mechanistically, beyond disruption of angiogenic signaling through placental insufficiency‐driven hypoxia and nutrient deprivation, emerging evidence implicates dysregulated metabolic and inflammatory signaling pathways, including reduced leptin signaling, altered cytokine networks (such as interleukin (IL)‐6–STAT3), and impaired fibroblast–myofibroblast function, all of which are critical for secondary septation and extracellular matrix remodeling during alveolarization [59, 60]. Collectively, these processes result in a structurally immature lung with reduced gas‐exchange surface area, thereby providing a mechanistic substrate for increased susceptibility to postnatal respiratory morbidity observed in FGR offspring.

4.2. Brain

Breakdown of the neurovascular unit—with reduced capillary density, increased blood–brain barrier permeability, and disturbed astrocyte–endothelial–pericyte coupling—marks the initial step of cerebral maladaptation and compromises nutrient and oxygen delivery [61]. This vascular dysfunction promotes activation of resident microglia through hypoxia and impaired barrier integrity. In turn, activated microglia amplify neurovascular unit disruption by generating a pro‐inflammatory milieu that further destabilizes endothelial–pericyte interactions and blood–brain barrier function [62]. These microglia release cytokines, such as IL‐1β, tumor necrosis factor alpha, and IL‐6, and undergo proteomic reprogramming, thereby contributing to secondary neuronal injury and white‐matter damage [63, 64]. In turn, sustained glial inflammation disrupts oligodendrocyte lineage maturation, leading to delayed myelination and reduced white‐matter integrity, a hallmark feature recapitulating the preterm‐like phenotype of FGR offspring. Consequently, neuronal populations exhibit diminished proliferation, impaired dendritic and axonal outgrowth, linking to aberrant synaptogenesis and long‐term neurodevelopmental deficits [65, 66].

Together, these studies delineate a cascading pathway in which placental insufficiency initiates vascular maladaptation, propagates glial and inflammatory activation, and culminates in disrupted myelin formation and neuronal maturation, thereby providing a mechanistic framework for the structural and functional brain abnormalities observed in growth‐restricted offspring.

4.3. Intestine

In FGR mouse models, a reduction in secretory epithelial lineages, including goblet and Paneth cells, has been consistently reported, suggesting impaired maturation of the intestinal mucosal barrier through diminished mucus and antimicrobial peptide production. Notably, Paneth cells are decreased in intestinal tissues from human FGR neonates, indicating that the cellular alterations observed in animal models may reflect clinically relevant features of the human disease [67]. Additionally, studies using porcine fetal growth restriction models have demonstrated increased intestinal permeability (“leaky gut”) accompanied by abnormalities in tight junction‐associated molecules, further supporting the contribution of structural barrier dysfunction to postnatal intestinal vulnerability [68].

Beyond the clinically recognized hemodynamic component, namely chronic intrauterine hypoperfusion [22], accumulating evidence indicates that coordinated intratissue stress responses are elicited within the growth‐restricted intestine. These include oxidative stress [68] and activation of stress‐adaptive programs, such as autophagy [31], which occur at the tissue level and may act upstream of the cellular phenotypes described above, contributing to loss of secretory epithelial lineages and impaired barrier maturation.

Epithelial lineage specification during intestinal development is governed by the Notch and Wnt signaling pathways, which establish the stage‐specific microenvironment of the crypt–villus unit [55]. However, whether and how Notch and Wnt signaling disruption directly mediates the intestinal phenotype associated with FGR has not yet been conclusively demonstrated.

4.4. Immune System

FGR is increasingly recognized to have effects on postnatal immune function; however, direct evidence in humans remains limited compared with the extensive literature on maternal and placental immunity. Most human studies relied on cord blood or early postnatal peripheral blood analyses, demonstrating alterations in cytokine and chemokine profiles and immune cell activation rather than consistent changes in immune cell composition. In term infants with SGA, cord blood biomarker analyses have shown selective reductions in inflammatory mediators, such as IL‐1β, suggesting an altered or hypo‐responsive innate immune state rather than generalized immune activation [69]. In preterm infants with FGR, longitudinal studies have reported sustained elevations in the level of chemokines, including IL‐8 and monocyte chemoattractant protein‐1, and increased proportions of activated monocytes and cytotoxic T cells during the neonatal period, indicating persistent immune activation despite relatively preserved overall leukocyte distributions [70]. Recent analyses of umbilical cord blood from growth‐restricted pregnancies have revealed shifts in circulating immune cell profiles, including expansion of central memory CD4⁺ and CD8⁺ T‐cell subsets, suggesting that altered T‐cell responsiveness is already established in utero [71].

Insights from large animal models provide complementary evidence that FGR primarily reprograms immune responsiveness rather than immune cell numbers. In porcine models of FGR, peripheral blood mononuclear cells exhibit blunted IL‐1β responses to lipopolysaccharide stimulation, impaired neutrophil phagocytic capacity, and increased regulatory T‐cell proportions, collectively pointing toward attenuated early innate immune defense and altered immune regulation [71, 72]. These functional immune deficits are associated with increased susceptibility to systemic infection, supporting the concept that FGR confers a state of immune vulnerability in the early postnatal period.

The clinical effect of this immune reprogramming is likely shaped by interactions between circulating immune activation and organ‐specific microenvironments, particularly at barrier organs that undergo rapid postnatal adaptation such as the intestine and lung. Local cues derived from epithelial integrity, microbial colonization, and tissue inflammation can modulate the phenotype and function of resident immune cells, thereby translating systemic immune bias into organ‐specific immune dysregulation [73]. In this context, FGR‐associated barrier immaturity and altered inflammatory signaling may predispose local immune compartments to maladaptive responses under postnatal stress.

Consequently, current evidence supports a functional immune bias in FGR, manifesting as altered inflammatory signaling and responsiveness, while the upstream drivers and cell‐type‐specific developmental pathways linking the intrauterine environment to postnatal immune phenotypes remain key unresolved questions.

5. Discussion

Placental dysfunction reframes perinatal complications not as isolated obstetric events, but as the starting point of disease susceptibility across the life course. The body of evidence summarized in this review demonstrates that the effects of PE and FGR do not end at birth; rather, they sequentially induce organ‐specific developmental adaptations.

From a mechanistic perspective, this review emphasizes how placental dysfunction is translated into organ‐specific molecular programs through shared upstream stressors, including hypoxia, oxidative stress, and inflammatory signaling. Experimental animal studies have played a central role in elucidating these pathways. Disruption of vascular–epithelial crosstalk in the lung, neurovascular unit impairment and microglial activation in the brain, imbalance of epithelial lineage specification and barrier dysfunction in the intestine, and functional immune reprogramming collectively suggest that multiple factors interact across organs via systemic and local signaling loops.

Nevertheless, substantial knowledge gaps remain. Cellular and molecular analyses of human fetal organs are intrinsically limited by ethical and technical constraints, necessitating cautious interpretation of findings derived from experimental models. Additionally, postnatal modifiers, including prematurity, neonatal intensive care exposures, nutrition, infection, and intestinal microbial colonization, interact dynamically with prenatal programming, complicating causal inference in clinical cohorts. These limitations underscore the need for long‐term, longitudinally designed, and deeply phenotyped human studies that integrate prenatal exposures with postnatal environments.

One of the major clinical challenges is risk stratification. Conventional ultrasonographic indices, such as umbilical artery Doppler, ductus venosus flow, and the cerebroplacental ratio, are indispensable for fetal surveillance and timing of delivery, and as described above, are associated with the incidence of neurodevelopmental, respiratory, and gastrointestinal morbidities. However, their resolution for predicting long‐term outcomes remains limited. Future risk prediction models are expected to incorporate biomarkers grounded in molecular mechanisms in addition to imaging data. Umbilical cord blood, which can be obtained non‐invasively at birth, represents a practical window into fetal immune and metabolic programming. Furthermore, advances in single‐cell analyses and spatial transcriptomics are increasingly enabling detailed interrogation of cellular heterogeneity and intercellular communication from limited samples, including placental tissue and neonatal specimens obtained for clinical indications. These approaches are expected to contribute to the identification of early biomarkers that define vulnerability and resilience.

Another important implication of this review is the potential for maternal or antenatal interventions aimed at modifying fetal programming pathways. Current management strategies for PE and FGR primarily focus on maternal stabilization and timing of delivery. However, there is growing interest in interventions targeting placental function, oxidative stress, inflammation, or epigenetic regulation. Although evidence for direct fetal benefit remains limited, appropriately timed maternal interventions may attenuate maladaptive developmental programming and improve postnatal outcomes. Careful evaluation of safety, timing, and long‐term efficacy will be essential for clinical translation of these strategies.

In conclusion, placental dysfunction represents an integrated biological foundation that links adverse intrauterine environments with organ‐specific developmental trajectories and lifelong disease risk. By integrating epidemiological evidence with molecular and experimental insights, this review highlights the need to shift perinatal care beyond a survival‐centered paradigm toward comprehensive care frameworks that incorporate biology‐informed risk stratification and preventive perspectives. Advancing this paradigm will require close collaboration across obstetrics, neonatology, developmental biology, and systems medicine to translate mechanistic understanding into improvements in lifelong health.

Author Contributions

Mari Ichinose: conceptualization, investigation, writing – original draft, writing – review and editing. Takayuki Iriyama: writing – review and editing, funding acquisition, supervision. Yasushi Hirota: funding acquisition, writing – review and editing, supervision.

Funding

This work was supported by Japan Agency for Medical Research and Development (JP25gn0110097) and JAOG Ogyaa Donation Foundation.

Conflicts of Interest

The authors declare no conflicts of interest.

Ichinose M., Iriyama T., and Hirota Y., “Placental Insufficiency and Neonatal Vulnerability: Organ‐Specific Mechanisms Shaping Early‐Life Health,” Journal of Obstetrics and Gynaecology Research 52, no. 2 (2026): e70202, 10.1111/jog.70202.

Data Availability Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this review.